Fifty-one children with acute lymphoblastic leukemia (ALL) in second or subsequent remission after a first remission of at least 2 4 months underwent purged, autologous bone marrow transplantation (ABMT). Bone marrow was harvested in remission and purged in vitro with monoclonal antibodies specific for leukemia-associated antigens. Ablative chemotherapy included cytarabine, teniposide, and cyclophosphamide followed by total body irradiation. Of the 51 patients treated between November 1980 and June 1991, 5 died of treatment-related complications, 1 8 relapsed, 1 died of a second tumor at 6.7 years, and 2 7 remained in continuous complete remission for a median of LTHOUGH the prognosis for children with newly di-A agnosed acute lymphoblastic leukemia (ALL) has improved in recent decades, most children with relapsed ALL have a poor prognosis. Chemotherapy alone is rarely curative.' Despite the use of modem, intensive chemotherapy regimens after relapse, event-free survival (EFS) at 5.5 years was only 30% for children with late relapse.* Disease-free survival (DFS) after allogeneic bone marrow transplantation (BMT) from matched sibling donors ranges from 40% to 75% for children with ALL in second or subsequent The lack of matched sibling donors, only 15% in a recent national pediatric trial, limits this approach." Attempts to expand the applicability of allogeneic BMT, including the use of marrow from mismatched related donors and matched unrelated donors, have met with mixed results."-13
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Extending intensive therapy to larger numbers of patients can be approached by using autologous BMT (ABMT). Most centers have used either pharmacologic or immunologic techniques to purge the bone marrow of residual leukemia cell^.'^-'^ Preclinical in vitro studies have shown that purging can reduce leukemic cell contamination of marrow by 3 to 4 logs. 16 The efficacy of purging in the clinical setting has never been conclusively shown but is strongly suggested from recent results with adult lymphoma patients. I9 We report the safety and efficacy of ABMT for 5 1 children with ALL in second or subsequent remission after a first remission of at least 24 months. Included in this population are 26 children previously reported by our center and an additional 25 children?'
PATIENTS AND METHODS
Eligibility criteria for Dana-Farber Cancer Institute (DFCI) ABMT protocols 80-056 and 87-026 included an initial diagnosis of acute lymphoblastic leukemia; age less than 18 years; at least one relapse and attainment of subsequent remission; lack of a suitable donor for matched allogeneic BMT; and CD9 and/ or CDlO expression on the leukemic cells. Before 1986 our institutional policy regarding selection of patients for ABMT was to recommend ABMT for all eligible patients whose first remission was less than 36 months and for some patients with a longer first remission. Subsequently, we recommended ABMT for all eligible patients. In 1989, the eligibility criteria were changed to exclude patients with a first remission less than 24 months who were treated on a separate ABMT protocol?' The majority of patients were referred from other Patient eligibility and selection.
3 9 months (range, 9 + to 124 + ). Event-free survival (EFS) ( f SE) at 3 years after ABMT was 53% f 7%. Leukemiafree survival (LFS) was 58% f 8%. In multivariate analysis, the most significant predictors of EFS were duration of longest pre-ABMT remission and remission duration immediately before ABMT. For LFS, the most significant predictors were cell dose per kilogram of marrow reinfused and duration of longest pre-ABMT remission. We conclude that ABMT for this population is an effective therapy available to the majority of children with relapsed ALL. 0 1993 by The American Society of Hematology.
institutions at the discretion of the individual treating physician whose recommendations may have differed from our own.
From November 1980 to June 199 I, 7 I children underwent ABMT according to the above DFCI protocols. Twenty patients with a first remission less than 24 months, including 18 reported previously, have been excluded from this Thus, 5 1 children with a first remission of at least 24 months are the subject of this report.
Patient characteristics are summarized in Table 1 . The only significant difference between the 15 patients treated before 1986 and the 36 treated subsequently was duration of first remission, 29 versus 38.5 months. This difference reflects the discontinuation of the upper limit on first remission duration described above. Twenty-two children had their initial relapse while receiving chemotherapy (N = 9) or within 6 months of cessation (N = 13). The median time to relapse after cessation of initial chemotherapy was 9 months (range, I to 41) for the 42 patients with an off-therapy relapse. The median duration of second remission was 35 months (range, 2 to 66) for the 20 patients transplanted in 3rd or 4th complete remission.
Therapy before ABMT is summarized in Table 2 . The majority of patients were initially diagnosed between 1980 and 1988 (N = 41) and treated with multiagent chemotherapy according to protocols currently in use at the refemng institutions and consisting of 5 or 6 systemic drugs (N = 44). The most common reinduction therapy after the last relapse before ABMT included prednisone, vincristine, asparaginase, and an anthracycline (N = 29). Only 5 patients failed to achieve complete remission within 1652 BILLETT ET AL Abbreviations: WBC, white blood cell count.
1 month of the last relapse before ABMT and required additional therapy to achieve remission. Forty-one patients received a cycle of moderate-dose cytarabine with an epipodophyllotoxin (N = 36) or high-dose cytarabine with or without other drugs (N = 5) after achieving complete remission (CR) but before ABMT. Seven ofthese patients had subsequent M2 marrow and/or a few blasts noted in Three failed to achieve CR until other therapy was given. t One failed to achieve CR until other therapy was given. Abbreviations: RT, radiation therapy; PT, patient; TBI, total body irradiation; BM, bone marrow relapse; CNS, CNS relapse; T, testicular relapse; CCR, continuous complete remission CNS disease at diagnosis and relapse.
the cerebral spinal fluid (CSF) and received additional therapy to induce a CR before ABMT.
Thirty children received cranial radiation during initial therapy. The cranial radiation doses for the 19 children with central nervous system (CNS) disease before ABMT are shown in Table 3 . Ofthe eleven boys with a prior testicular relapse, 10 received at least 2,400 cGy to the testis after relapse and before ABMT.
The protocols were approved by the appropriate institutional review boards and informed consent was obtained for all patients.
In 1988, we instituted a policy of additional or "boost" radiation therapy immediately before TBI to sites of prior extramedullary disease for patients who had received 5 1,800 cGy to the cranium or no prior testicular radiation. Five children who had no prior cranial radiation received 950 to 1,050 cGy additional radiation therapy to the cranium (Table 3) , and one child received 1,000 cCy to the testes.
In addition, 2 patients in the early years of the program received 540 to 900 cGy to the craniospinal axis just before TBI despite previous cranial irradiation of 2 1,800 cGy. After March 1986, all patients received a conditioning regimen consisting of intravenous (IV) teniposide 200 mg/M2 on days -8 and -6; IV cytarabine 3 g/m2 every 12 hours on days -8, -7, and -6; IV cyclophosphamide 1,800 mg/m2 on days -5 and -4; and TBI of 1,400 cGy at 10 cGy/min, 175 cGy per fraction twice daily as previously reported." Different cytarabine and TBI doses were used in the 15 patients treated before this time. 20 Following the last dose of irradiation, the antibody-treated autologous bone marrow was thawed and infused intravenously over 15 to 30 minutes. No chemotherapy or immunosuppressive medication was administered after transplantation. All patients were treated in Pretransplant radiation therapy.
Patient treatment.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org single rooms, and the last 42 were isolated in HEPA-air filtered rooms. Oral nonabsorbable antibiotics were administered 4 times daily.
Ten to 15 cm3/kg of bone marrow was harvested and treated as previously described with three cycles of J5 anti-CALLA (anti-CD 10) and 52 anti-GP26 (anti-CD 9) monoclonal antibodies and complement?' The first five marrows were treated with a single monoclonal antibody, all others with both monoclonals. The median time from bone marrow harvest to reinfusion was 13 days (range, 8 to 26).
Remission was defined as less than 5% blasts in the marrow and no evidence of extramedullary leukemia. Relapse was defined as greater than 25% lymphoblasts in the bone marrow or evidence of extramedullary leukemia. For analysis of EFS, events were defined as relapses, remission deaths, or second tumors, and times were calculated from the day of bone marrow infusion. For analysis of leukemia-free survival (LFS), events were defined as relapses; remission deaths and second tumors were counted as censored observations. All deaths, regardless of cause, were counted for the analysis of overall survival. The Kaplan-Meier method was used to estimate EFS and LFS and Greenwood's formula was used to estimate standard Results were summarized by percentage of 3-year EFS or LFS ? standard error (SE). The two-sided log-rank procedure was used to assess the statistical significance of differences between patient subgroups with respect to EFS and LFS di~tributions?~ The influence of potential prognostic factors on outcome was evaluated in multivariate analyses using the Cox proportional hazards regression model." Data were analyzed as of January 31, 1992.
Marrow treatment in vitro.
Statistical methods.
RESULTS
Thirty-one of the 5 1 children remained alive at a median follow-up for the surviving patients of 3 1 months (range, 6 to 124). The overall survival percentage (+SE) was 63% (+7) at 3 years, 55% (+8) at 4 years, and 47% (+lo) at 7 years, the time of the latest death.
EFS and LFS for all patients are shown in Fig 1. The 3-year EFS (+SE) was 53% (+7), and the 3-year LFS was 58% (+8). The median follow-up of the 27 patients surviving in continuous complete remission was 39 months (range 9+ to 124+). Five patients died early of treatment-related compli-
Survival.
cations, 18 relapsed, and one developed a second tumor (acute myelogenous leukemia) at 6.7 years. There were no statistically significant differences in outcome between the 15 patients receiving transplants before 1986 and the 36 treated subsequently (Table 4) .
In univariate analyses, duration of longest remission before ABMT and cell dose per kilogram were the most significant predictors of both EFS and LFS (Table 5 and Figs 2 and 3) . When analyzed by cell dose, the distribution of other factors was well balanced. However, in multivariate analyses of the same factors, the most significant predictors of EFS were duration of longest remission before ABMT (P = .07) and remission duration just before BMT (P = .07). The most significant predictors of LFS remained cell dose per kilogram (P = .025) and longest remission before ABMT (P = .06).
There was no significant difference in EFS for the 22 patients whose initial relapse was on therapy or within 6 months after cessation of therapy versus the 29 who relapsed subsequently (P = .38). We analyzed the effect of prior therapy on EFS after ABMT and found that none of the following factors had any significance: (1) year of diagnosis before 1982 versus subsequently; (2) reinduction before ABMT with prednisone, vincristine, asparaginase, and an anthracycline versus any other regimen; and (3) use of moderate or high-dose cytarabine after the last reinduction regimen before ABMT and transplant versus not using cytarabine in this time period. Because only 18 leukemic relapses and 24 total events have occurred, the absence of statistical significance for various factors does not necessarily mean that these factors do not carry any prognostic significance.
Neutrophil engraftment with an absolute neutrophil count 25OO/pL occurred at a median of 26 days (range, 12 to 68); whereas platelet engraftment with a platelet count 22O,OOO/pL occurred at a median of 39 days (range, 13 to 1 10). Cell dose 2 lo8 cells/kg and more recent treatment era were important independent predictors of more rapid neutrophil engraftment (P = .OS, P = .06, respectively) and platelet engraftment (P = .lo, P = .OS, respectively) in multivariate Cox models. Although engraftment could not be documented by peripheral blood counts in the 5 patients who died early of treatment-related causes, islands of hematopoiesis were seen in all three postmortem examinations performed.
Five patients died of transplantation-related complications including disseminated aspergillosis ( l), interstitial pneumonitis of unknown etiology
Engraftment.
Transplantation-related mortality. Remission no at BMT (2), Candida sepsis (l), and vaso-occlusive disease (1). The median time to death was 21 days (range, 9 to 33). More deaths occurred before 1986 (33%, 3 of 15) than subsequently (5.6%, 2 of 36; P = . I 1). Four of these deaths occurred among the 27 patients who received less than 10' cells/kg of marrow. The median duration of first remission in these patients was 30 months (range, 25 to 46). The most common site of relapse was bone marrow alone (N = 14) or combined with the CNS (N = 1) or testicle (N = 1). Two isolated extramedullary relapses occurred: one in the CNS and one in the retroorbital space. Thus, 39% (1 8 of 46) of patients who did not die early from toxicity relapsed. The median time to relapse was 8 months (range, 2 to 29). Thirteen relapses occurred within 1 year of transplant. Three of the 5 late relapses occurred in patients with isolated extramedullary disease before ABMT. Of the 25 boys with no prior testicular relapse, one had a combined bone marrow and testicular relapse after ABMT. No isolated testicular relapses occurred.
Relapse after transplantation.
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Control of prior extramedullary disease. Of the 19 patients who had any CNS disease before ABMT, l died early from treatment complications, 6 had a subsequent relapse (3 BM, 1 BM/T, 1 BM/CNS, 1 CNS), and 12 remained in CCR ( Table 3) . We examined the effect of prior CNS radiation on the risk of CNS relapse among the 18 patients at risk. No CNS relapses after ABMT occurred in the 15 patients ( Table  3 : numbers 2 to 16) who had received greater than 1,800 cGy to the cranium before ABMT or who had received additional cranial "boost" irradiation plus TBI. Of note, 10 of these 15 received cranial irradiation after their last known CNS disease. In contrast, two of three patients ( Table 3 : numbers 17 to 19) with ~1,800 cGy to the cranium before ABMT and no additional cranial irradiation with TBI had a CNS relapse after ABMT (P = .02). None of 11 boys with a prior testicular relapse had a testicular relapse after ABMT.
We evaluated the phenomenon of remission-inversion, that is, achieving a posttransplant re- For personal use only. on October 30, 2017. by guest www.bloodjournal.org From mission longer than the longest pretransplant remission. Twelve patients achieved remission-inversion; none have relapsed, and one developed a second tumor. The remaining patients include 5 who died from toxicity, 18 who relapsed before achieving remission-inversion, and 16 who have not been observed long enough to achieve remission-inversion.
Remission-inversion.
Of the five patients with isolated extramedullary disease before ABMT, three relapsed after transplantation (bone marrow and testicle, CNS, and retro-orbital space) and two remain in CCR. EFS for this small group of patients was 40% (+22).
Isolated extramedullary disease.

DISCUSSION
This study reports the outcome of ABMT after relapse for 51 children with ALL whose first remission was at least 24 months. Three-year EFS was 53% (+7) and LFS was 58% (k8). Early remission deaths occurred in 10% of patients (5 of 5 l), and relapse occurred in 35% (1 8 of 5 1).
In multivariate analyses, the duration of longest remission before ABMT was one of the most significant predictors of both EFS and LFS. This finding may reflect the slower proliferative rate of the leukemic cells in patients with a very long remission. The next most significant predictor of EFS was remission duration immediately before ABMT. Two possible explanations for this observation include (1) less residual leukemia in patients who receive more chemotherapy immediately before ABMT and (2) exclusion of patients who relapse again before ABMT. In contrast to some allogeneic BMT remission number greater than 2 was not an adverse prognostic factor. This may be attributable to the long durations of second remission (median, 35 months) for patients transplanted in 3rd or 4th remission. Although leukocyte count at diagnosis is an indication for more intensive initial therapy, it was not a prognostic factor for outcome after ABMT. This is analogous to the loss of significance of original prognostic factors for patients in first remission for more than 24 months. 25 We were unable to identify any treatment factor, either initial or after relapse, that was a significant predictor of EFS after ABMT.
Among patients who received an infusion of 210' cells/ kg of marrow, there was faster engraftment, fewer early remission deaths, and lower EFS and LFS. One possible explanation of the lower LFS and EFS in these patients is reinfusion of more residual leukemia that would contribute to an increased risk of relapse. In the future, analysis of minimal residual disease burden may clarify this issue.
Deaths from complications of treatment decreased from 33% before 1986 to 5.6% subsequently. Despite this decrease in toxicity, EFS did not change. Possible explanations of this observation are (1) more relapses occurring in patients who are now surviving the immediate posttransplant period and (2) more refractory leukemia in patients who relapsed after more intensive, modem initial therapy. Because the median time to early death from toxicity was shorter than the median time to both neutrophil and platelet engraftment, we do not know if delayed engraftment contributed to these deaths.
Control of prior extramedullary disease was good. Of 18 patients with prior CNS disease at risk for relapse after ABMT, only 2 had a subsequent CNS relapse. Both of these relapses occurred in patients who had received inadequate cranial radiation: I 1,800 cGy of cranial radiation before ABMT and no boost cranial radiation just before TBI. After these two relapses occurred, we initiated a policy of boost cranial irradiation before TBI for all such patients. No boy with a testicular relapse before ABMT had a subsequent testicular relapse.
Although some centers give additional radiation therapy to the testis with TBI to reduce the risk of testicular relapse in boys without a history of testicular relap~e,~ our data do not support this. Of 25 boys with no testicular relapse and, thus, no additional testicular radiation before or during TBI, no isolated testicular relapses occurred. Of these 25, one had a combined bone marrow and testicular relapse.
None of 12 patients in this series who achieved remissioninversion has had a subsequent relapse. This observation suggests that remission-inversion may be a definition of cure in these patients.
Our results with a 3-year EFS of 53% compare favorably with previous studies that have reported disease-free survival of 8% to 33% for patients with a long first remission treated with chem~therapy.~.~~"' Direct comparisons between these studies and ours are difficult because chemotherapy programs follow patients from the time of relapse, whereas our patients not only achieved remission but also stayed in remission long enough to undergo ABMT. A recent report of the outcome for children in second remission who were treated with intensive chemotherapy both initially and after relapse showed an LFS of 41% for patients with a first remission of at least 18 months who were in remission at day 125.32 These results are similar to the LFS of children in our study who underwent ABMT. However, almost 40% of our patients were in 3rd or 4th remission.
Although EFS or LFS ranged from 40% to 65% for children with relapsed ALL after matched, sibling-donor allogeneic BMT, donor availability severely limits the applicability of this The mortality of allogeneic BMT was higher (20% to 30%) than in our series (lo%), a difference attributed to the occurrence of graft-versus-host disease.
Our results compare favorably with other reports of ABMT for childhood ALL after relapse. In one report of ABMT for 56 children with ALL in second or subsequent remission, DFS was 21%, and toxic deaths occurred in 8%. 33 In another report of 24 children, DFS was 45% and toxic deaths occurred in 17%.34 Both studies used a variety of purging and conditioning regimens and included patients with a short first remission. Investigators from Minnesota have reported DFS of 22% for 69 children and adults with ALL who underwent ABMT.35 The majority of patients received transplants after relapse, and all patients received marrows purged with monoclonal antibodies, some with 4-hydroperoxycyclophosphamide in addition. The conditioning regimen included TBI for all patients, with either cytarabine or cyclophosphamide. The best results (42% DFS) were in the group of patients with the longest median duration of first remission, 31.9 months. The outcome of only pediatric patients was not reported.
We conclude that ABMT is a good alternative to continuation chemotherapy after relapse for patients with a long For personal use only. on October 30, 2017. by guest www.bloodjournal.org From first remission who do not have an appropriate donor for allogeneic BMT. The outcome of ABMT for patients with a short first remission will be the subject of a separate publication. Initial leukocyte count, prior extramedullary disease, and remission number at ABMT were not prognostic factors, whereas remission duration and celldose of marrow reinfused were. Control of extramedullary disease was good in our series, but bone marrow relapse was a major problem. Future efforts will need to be directed to this area. 
